To test this prediction, we assessed the phosphorylation status of NELF-A in three representative cancer cell lines harboring various ERK-activating oncogenes: A431 (EGFR amplification), H1299 (NRasQ61K), and A375 (BRafV600E). The gene discussed is MAPK1; the disease is cancer.